Table 1 Baseline Sample Characteristics
From: Validation of a patient satisfaction questionnaire for anemia treatment, the PSQ-An
Darbepoetin alfa (n = 157) | Epoetin alfa (n = 155) | |
|---|---|---|
Sex, n (%) | ||
Male | 23 (15) | 26 (17) |
Female | 134 (85) | 129 (83) |
Race, n (%) | ||
White | 132 (84) | 131 (85) |
Black | 16 (10) | 11 (7) |
Hispanic | 3 (2) | 6 (4) |
Asian | 6 (4) | 5 (3) |
Other | 0 (0) | 2 (2) |
Age (years) | ||
Mean (SD) | 58.7 (11.5) | 61.7 (12.1) |
Tumor type, n (%) | ||
Breast | 72 (46) | 69 (45) |
Non Small Cell Lung (stage IIIb/IV) | 51 (32) | 51 (33) |
Gynecologic | 34 (22) | 35 (23) |
Stage of Disease | ||
I/II | 41 (26) | 28 (18) |
III | 29 (18) | 27 (17) |
IIIb | 15 (10) | 14 (9) |
IV | 70 (45) | 81 (52) |
Unknown | 2 (1) | 5 (3) |
Karnofsky Performance Status, n (%) | ||
100 | 18 (11) | 18 (12) |
80, 90 | 104 (66) | 103 (67) |
60, 70 | 35 (22) | 33 (22) |
≤50 | 0 (0) | 1 (1) |
Hb (g/dL) | ||
Mean (SD) | 10.4 (0.8) | 10.4 (0.8) |
Median | 10.6 | 10.6 |
Hb, n (%) | ||
<10 g/dL | 38 (24) | 38 (25) |
≥10 g/dL | 119 (76) | 117 (75) |